Michel Schummer

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection
    Michel Schummer
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 5:e9122. 2010
  2. pmc Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125
    Michel Schummer
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Gynecol Oncol 125:65-9. 2012
  3. doi request reprint Breast cancer genomics: normal tissue and cancer markers
    Michel Schummer
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Ann N Y Acad Sci 1210:78-85. 2010
  4. ncbi request reprint The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma
    Ingegerd Hellstrom
    Pacific Northwest Research Institute, Seattle, Washington 98122, USA
    Cancer Res 63:3695-700. 2003
  5. pmc Activation of the MEK-S6 pathway in high-grade ovarian cancers
    Aviva P Ventura
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Appl Immunohistochem Mol Morphol 18:499-508. 2010
  6. ncbi request reprint Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q
    Brad Stone
    Benaroya Research Institute at Virginia Mason Research Center, Seattle, WA 98101 2795, USA
    Int J Cancer 104:73-84. 2003
  7. ncbi request reprint Selecting differentially expressed genes from microarray experiments
    Margaret Sullivan Pepe
    Department of Biostatistics, University of Washington, Seattle, Washington 98195 7232, USA
    Biometrics 59:133-42. 2003
  8. pmc Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains
    Vitor M Faca
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 3:e2425. 2008

Collaborators

Detail Information

Publications8

  1. pmc Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection
    Michel Schummer
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 5:e9122. 2010
    ....
  2. pmc Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125
    Michel Schummer
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Gynecol Oncol 125:65-9. 2012
    ..Evaluate and compare the effectiveness of CA125, HE4, Mesothelin and MMP7 marker levels to monitor ovarian cancer patients after surgery and chemotherapy. Evaluate the lead time of a rise of marker levels before recurrence...
  3. doi request reprint Breast cancer genomics: normal tissue and cancer markers
    Michel Schummer
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Ann N Y Acad Sci 1210:78-85. 2010
    ..Here we report the identification of potential breast cancer markers, including some that are overexpressed in aggressive disease...
  4. ncbi request reprint The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma
    Ingegerd Hellstrom
    Pacific Northwest Research Institute, Seattle, Washington 98122, USA
    Cancer Res 63:3695-700. 2003
    ..However, the HE4 assay may have an advantage over the CA125 assay in that it is less frequently positive in patients with nonmalignant disease...
  5. pmc Activation of the MEK-S6 pathway in high-grade ovarian cancers
    Aviva P Ventura
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Appl Immunohistochem Mol Morphol 18:499-508. 2010
    ..The phosphorylation of S6 as a specific biomarker for either MEK or PI3-kinase pathway activation should be used with caution...
  6. ncbi request reprint Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q
    Brad Stone
    Benaroya Research Institute at Virginia Mason Research Center, Seattle, WA 98101 2795, USA
    Int J Cancer 104:73-84. 2003
    ..Thus, these abnormal expression patterns combined with the endogenous immune response suggests that these antigens represent potential targets for immunotherapy...
  7. ncbi request reprint Selecting differentially expressed genes from microarray experiments
    Margaret Sullivan Pepe
    Department of Biostatistics, University of Washington, Seattle, Washington 98195 7232, USA
    Biometrics 59:133-42. 2003
    ..Our approach leads naturally to a procedure for sample-size calculations, appropriate for exploratory studies that seek to identify differentially expressed genes...
  8. pmc Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains
    Vitor M Faca
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 3:e2425. 2008
    ..We have characterized the cell surface proteome and the proteins released into the extra-cellular milieu of three ovarian cancer cell lines, CaOV3, OVCAR3 and ES2 and of ovarian tumor cells enriched from ascites fluid...